Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Thyroid stimulating immunoglobulins in Graves' disease with goitre growth, low thyroxine and increasing triiodothyronine during PTU treatment

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Urinary growth hormone excretion in acromegaly: diagnostic value in mild disease activity

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Impaired pancreatic polypeptide response to a meal in type 1 diabetic patients: vagal neuropathy or islet cell dysfunction?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Bone metabolism in obesity: changes related to severe overweight and dietary weight reduction.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Effects of thyrotropin-releasing hormone on regional cerebral blood flow in man

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
In 50 consecutive patients with Graves' disease treated with PTU, 7 (group 1) developed increasing goitre in spite of unmeasurable TSH. Thyroid variables were compared with those from 10 controls with an ordinary response to PTU (group 2). Serum T4 decreased in group 1 from 246 +/- 47 nmol/l (mean +/- SD) to 40 +/- 9 nmol/l after 6 weeks of PTU treatment and continued to be below the normal range during the next 4 months. In group 2 serum T4 decreased from 190 +/- 35 to 88 +/- 47 nmol/l and stayed in the normal range. Serum T3 was normalized in both groups after 6 weeks but increased to values above the normal range in group 1 after that time. In spite of unmeasurable TSH during the 6 months of treatment in group 1, thyroid volume, determined ultrasonically, increased significantly from 60 +/- 29 to 93 +/- 68 ml (P less than 0.05), but was unaltered in group 2 about 25 ml. Thyroid stimulating antibodies (TSAb) measured by adenylate cyclase activation (normal below 109%) decreased in group 2 from 117 +/- 23 to 90 +/- 17% (P less than 0.01) (6 months of therapy), but increased significantly in group 1, from 201 +/- 47% to a maximum value of 234 +/- 69% (P less than 0.05). TSH binding inhibitory immunoglobulins (TBII) (given as per cent inhibition, normal below 26%) decreased in group 2 from 43 +/- 29 to 29 +/- 27% (P less than 0.05) but were unaltered high in group 1, 66 +/- 25% before therapy and 57 +/- 26% after 6 months of therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
Original languageEnglish
JournalActa Endocrinologica (Copenh)
Volume107
Issue number4
Pages (from-to)482-8
Number of pages7
ISSN0001-5598
Publication statusPublished - Dec 1984

    Research areas

  • Adult, Antibodies, Female, Graves Disease, Humans, Immunoglobulin G, Immunoglobulins, Thyroid-Stimulating, Male, Middle Aged, Propylthiouracil, Thyroid Gland, Thyroxine, Triiodothyronine

ID: 43045944